Abstract:This article describes the main conclusions drawn from the presentations on Helicobacter pylori infection in Digestive Diseases Week, 2016. Despite the undeniable widespread reduction in the prevalence of this infection, infection rates continue to be high in developing countries. The prevalence of clarithromycin, metronidazole and quinolone resistance is markedly high in most countries and continues to rise. The management of H. pylori infection in patients with peptic ulcers still leaves much to be desired. Although H. pylori eradication reduces the incidence of gastric adenocarcinoma, it does not completely avoid its appearance. The new rapid stool antigen tests show promising results. The efficacy of standard triple therapy is clearly inadequate and continues to decline, and cannot therefore be recommended. Vonoprazan, when associated with 2 antibiotics, is more effective than traditional proton pump inhibitors, especially in clarithromycin-resistant patients. Non-bismuth quadruple (concomitant) therapy achieves eradication rates of around 90% and has a good safety profile. Concomitant therapy is more effective and simpler than sequential therapy. Although some probiotics can increase the efficacy and tolerability of triple therapy, the utility of its association with quadruple concomitant therapy has not been established. If a first treatment with clarithromycin fails, both bismuth-containing quadruple therapy and levofloxacin-containing triple therapy achieve good-but still suboptimal-results. The combination of bismuth and levofloxacin in the same regimen increases the efficacy of rescue therapy. The management of H. pylori infection by European gastroenterologists is widely heterogeneous and the eradication rates achieved by them are generally unacceptable. In Spain, the highest first-line eradication rate is obtained with quadruple concomitant therapy in 14-day regimens and with double doses of proton pump inhibitors; in second-line therapy, the use of levofloxacin- and bismuth-containing quadruple therapy improves the rates traditionally obtained with quinolones. On the other hand, there is a clear disconnect between the recommendations made in consensus documents and clinical practice in primary care.

Helicobacter pylori infection and antibiotic resistance: a WHO high priority?

Review article: the global emergence of Helicobacter pylori antibiotic resistance

Helicobacter pylori infection and antibiotic resistance — from biology to clinical implications

Antibiotic Resistance, Susceptibility Testing and Stewardship in Helicobacter pylori Infection

Helicobacter Pylori infection; the challenging task of improving eradication rates in light of rising antibiotic resistance, a literature review

Helicobacter pylori in the post-antibiotics era: from virulence factors to new drug targets and therapeutic agents

Rapid diagnosis and precision treatment of Helicobacter pylori infection in clinical settings

Antibiotic resistance of Helicobacter pylori isolated in the Southeast Coastal Region of China.

Revolution of Helicobacter pylori treatment

From Antibiotic Resistance to Antibiotic Renaissance: A New Era in Helicobacter pylori Treatment

Epidemiology of Helicobacter pylori Resistance to Antibiotics (A Narrative Review)

The effect of antibiotic resistance on Helicobacter pylori eradication efficacy: A systematic review and meta‐analysis

Helicobacter pylori Antimicrobial Resistance and the Role of Next-Generation Sequencing

Helicobacter pylori Antibiotic Resistance: Molecular Basis and Diagnostic Methods

Helicobacter pylori-related diseases

Current and Future Treatment of Helicobacter pylori Infections

Molecular Mechanisms of Antibiotic Resistance and Novel Treatment Strategies for Helicobacter pylori Infections

Development of Helicobacter pylori treatment: How do we manage antimicrobial resistance?

Recent progress in Helicobacter pylori treatment

Global Primary Antibiotic Resistance Rate of Helicobacter pylori in Recent 10 years: A Systematic Review and Meta‐Analysis

Antibiotic Resistance of Helicobacter pylori : Mechanisms and Clinical Implications